by 
Rabies antiserum is a type of immunoglobulin that provides temporary immunity against rabies in humans immediately after exposure to the rabies virus. It contains antibodies against the rabies virus and is administered to exposed individuals before the onset of symptoms. Rabies antiserum is highly effective when administered promptly following exposure. It acts as a temporary vaccine by providing passive immunity through pre-formed antibodies until the exposed person develops their own antibodies. Besides individuals, rabies antiserum is also frequently used in veterinary practices to vaccinate cattle and dogs against rabies infections. The global rabies antiserum market is estimated to be valued at US$ 1.24 Bn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Driver 1: Rising incidences of dog bites in developing countries: Developing regions such as Asia Pacific and Africa have a high prevalence of stray dogs and limited rabies vaccination programs. This has significantly contributed to the rising number of dog bite cases in these areas. For instance, according to the World Health Organization (WHO), around 59,000 people die every year worldwide due to rabies, with the majority of cases reported from Asia and Africa. Moreover, it has been observed that India alone accounts for over 35% of the global rabies deaths annually. Therefore, the increasing incidences of dog bites, especially in developing nations is driving the demand for rabies antiserum for post-exposure prophylaxis and helping bolster the market growth over the forecast period.
Driver 2: Increasing awareness regarding rabies prevention: Various nonprofit organizations and government initiatives are raising awareness about rabies prevention through mass dog vaccination programs and encouraging prompt medical aid after exposure. This has positively impacted the early administration of rabies antiserum post-exposure in high infection regions, thereby elevating the demand. Additionally, favorable government policies supporting routine dog vaccination are anticipated to create a lucrative market scenario for rabies antiserum.
Segment Analysis
The global rabies antiserum market is segmented into by animal type, and end user. Based on animal type, the market is segmented into dogs, cats, and other animals. The dogs segment dominates the market and accounts for around 60% market share in 2024. Dogs are more susceptible to rabies virus as compared to other animals. Based on end user, the market is segmented into hospitals, clinics, and other facilities. The hospitals segment dominates the market owing to high patient footfall and availablity of advanced healthcare facilities for animal treatment.
PEST Analysis
Political: Regulations regarding animal healthcare and vaccines are favorable in developed regions which is driving the market growth. Some developing nations still lack strict policies for animal welfare.
Economic: Rising animal healthcare expenditure is supporting the market growth. Growth in pet ownership and increasing cases of rabies in animals globally are increasing the demand.
Social: Rising affection towards pets is positively impacting the market. People are more concerned about animal health which is supporting treatment and vaccine uptake.
Technological: Advancements in rabies vaccine production technologies are helping manufacturers meet the growing demand. Cold chain logistics for temperature sensitive products distribution is improving globally.
Key Takeaways
The global rabies antiserum market size was valued at US$ 1.24 Bn in 2024 and is anticipated to reach US$ 1.78 Bn by 2030, expanding at a CAGR of 3.3% during the forecast period.
North America dominated the market in 2024 owing to stringent animal welfare policies and high healthcare expenditure.
Major players operating in the rabies antiserum market are CSL Behring, Sanofi, GlaxoSmithKline, and other prominent players. Key players are focusing on capacity expansion and new product launches to strengthen their product portfolios. CSL Behring holds over 30% market share owing to its vast product range and global distribution network.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
